ADVM Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of -101870.49%. Adverum Biotechnologies's return on equity of -69.14% beat Editas Medicine's return on equity of -74.59%.

Adverum Biotechnologies has a consensus price target of $30.00, signalling upside risk potential of 526.88%. On the other hand Editas Medicine has an analysts' consensus of -- which suggests that it could grow by 203.03%. Given that Adverum Biotechnologies has higher upside potential than Editas Medicine, analysts believe Adverum Biotechnologies is more attractive than Editas Medicine.

Adverum Biotechnologies has a beta of 0.912, which suggesting that the stock is 8.787% less volatile than S&P 500. In comparison Editas Medicine has a beta of 1.864, suggesting its more volatile than the S&P 500 by 86.439%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are larger than Editas Medicine quarterly revenues of $61K. Adverum Biotechnologies's net income of -$27.1M is higher than Editas Medicine's net income of -$62.1M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 1.61x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Pharmaceuticals has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of -278.99%. Adverum Biotechnologies's return on equity of -69.14% beat EyePoint Pharmaceuticals's return on equity of -50.67%.

Adverum Biotechnologies has a consensus price target of $30.00, signalling upside risk potential of 526.88%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.45 which suggests that it could grow by 356.41%. Given that Adverum Biotechnologies has higher upside potential than EyePoint Pharmaceuticals, analysts believe Adverum Biotechnologies is more attractive than EyePoint Pharmaceuticals.

Adverum Biotechnologies has a beta of 0.912, which suggesting that the stock is 8.787% less volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.455, suggesting its more volatile than the S&P 500 by 45.456%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $10.5M. Adverum Biotechnologies's net income of -$27.1M is higher than EyePoint Pharmaceuticals's net income of -$29.4M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 8.13x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of -246.3%. Adverum Biotechnologies's return on equity of -69.14% beat Regenxbio's return on equity of -69.62%.

Adverum Biotechnologies has a consensus price target of $30.00, signalling upside risk potential of 526.88%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 408.6%. Given that Adverum Biotechnologies has higher upside potential than Regenxbio, analysts believe Adverum Biotechnologies is more attractive than Regenxbio.

Adverum Biotechnologies has a beta of 0.912, which suggesting that the stock is 8.787% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are smaller than Regenxbio quarterly revenues of $24.2M. Adverum Biotechnologies's net income of -$27.1M is higher than Regenxbio's net income of -$59.6M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 4.19x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Cassava Sciences's return on equity of --.

Adverum Biotechnologies has a consensus price target of $30.00, signalling upside risk potential of 526.88%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4857.27%. Given that Cassava Sciences has higher upside potential than Adverum Biotechnologies, analysts believe Cassava Sciences is more attractive than Adverum Biotechnologies.

Adverum Biotechnologies has a beta of 0.912, which suggesting that the stock is 8.787% less volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are larger than Cassava Sciences quarterly revenues of --. Adverum Biotechnologies's net income of -$27.1M is higher than Cassava Sciences's net income of -$27.9M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 2.57x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.